Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canad.

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in Philadelphia, Pennsylvania and at the 2023 American College of Rheumatology Convergence (ACR), ta.

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for diseases with high unmet medical need. The company has been the subject of frequent takeover rumors and continues to gain impressive sales traction with its primary drug compound. The shares have been a roller coaster ride in recent years. Where does the stock go from here? An updated analysis follows in the paragraphs from here.

Aurinia Pharmaceuticals: Reassessing As It Gains Traction

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital.

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The biotech's shares have been trading at a premium all year long.

Why Aurinia Pharmaceuticals Stock Is Slumping Today

Alpine Immune Sciences

Corcept Therapeutics

Cardiol Therapeutics

KalVista Pharma

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

The average of price targets set by Wall Street analysts indicates a potential upside of 42.9% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership.

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright David Martin - Bloom Burton Farzin Haque - Jefferies Justin Kim - Oppenheimer Operator Greetings.

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.25 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts are expressed in U.S. dollars. Total net revenue was $41.5 million for the three months ended June 30, 2023, compared to $28.2 million in the prior year three months ended June 30, 2022, representing growth of approximately 47% year over year. Year to date net revenue increased to $75.9 million for t.

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023.

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal of the American College of Rheumatology. As part of the AURORA Clinical Program, the AURORA 2 extension study assessed the long-term safety and tolerability of LUPKYNIS® (voclosporin), compared.

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), the beneficial owner of approximately 4.2% of the outstanding common shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today commented on the Company's decision to initiate a review of strategic alternatives, including a potential value-maximizing sale, following MKT Capital's successful withhold campaign at the Company's 2023 Annual General Meeting of Share.

MKT Capital Pleased with Aurinia's Commencement of a Strategic Review Process

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?

Thursday, Aurinia's board of directors announced plans to explore strategic alternatives to bolster shareholder value. Investors are piling into the biotech's shares today as a result.

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday.

Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout

Shares of Aurinia Pharmaceuticals ( US:AUPH ) are up almost 14% in Friday's premarket activity following a series of director departures and news of a strategic review of potential sale or merger opportunities.

Aurinia Pharmaceuticals Share Surge Shows Investor Support for Board Reboot, Strategic Review

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value.

Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy.

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range was increased to between $135 to $155 million of net product sales. The lupus nephritis treatment market is expected to reach $5.67 billion by 2033.

Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria in lupus nephritis (LN) patients with high proteinuria across biopsy classes, races, and ethnicities. These data w.

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today condemned the Company's sluggish response to the outcome of its 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023. At the Annual Meeting, Chairman George Milne and Com.

News for Aurinia Pharmaceuticals Stock (AUPH)